MRNA Stock Price and Chart — BCBA:MRNA

Overview

Financials News Ideas Discussions Technicals Seasonals

Key facts today

Moderna's Q2 2025 revenue dropped 41% to $142 million, mainly from COVID shot sales. The company lowered its full-year revenue outlook to $1.5-$2.2 billion, causing shares to fall 7.1%.

Moderna executives announced plans to reduce the company's headcount to under 5,000 by the end of the year, down from 5,800 at the beginning of 2025.

Analyze the impact Analyze the impact

About Moderna, Inc.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Check out other big names from the same industry as MRNA.